Compare Amgen, Inc. (AMGN) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Fastly Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Fastly Inc trades at $19.5 (market cap $3.07B). The key difference: Amgen, Inc. is far larger — about 63.9× Fastly Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| AMGN | FSLY | |
|---|---|---|
Market Cap | $196.12B | $3.07B |
Sector | Health | Technology |
52-Week High | $388.16 | $33.50 |
52-Week Low | $271.18 | $6.36 |
Enterprise Value | $241.41B | $3.13B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Fastly (FSLY) trades at $19.59, down 3.64% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth accelerated to 20% year-over-year in Q1 2026, though the company remains unprofitable with a net margin of -19.5% in 2025. Analyst consensus is mixed with a $25.80 price target, while recent news highlights partnerships and AI-driven compute growth.
The outlook is cautiously optimistic: continued revenue expansion and margin improvement offer upside potential, but persistent losses and competitive pressures pose risks. Investors should weigh the stock's discounted valuation against execution challenges in a crowded edge cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
